Neurogene to Participate in Upcoming Investor Conferences
Neurogene (NGNE) management will participate in fireside chats and investor meetings at two upcoming healthcare investor conferences.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Guggenheim 3rd Annual Healthcare Innovation Conference
Format: Management will participate in a fireside chat and investor meetings
Date: Tuesday, November 10 at 10:30 a.m. ET
Stifel 2026 Healthcare Conference
Format: Management will participate in a fireside chat and investor meetings
Date: Wednesday, November 11 at 10:40 a.m. ET
Live webcasts of the fireside chats will be accessible from the Investor Relations section of Neurogene’s website under Events & Presentations, where replays of the events will also be available for a limited time.
About Neurogene
Neurogene (Nasdaq: NGNE) is a clinical-stage biotechnology company focused on developing life-changing genetic medicines for people and their families impacted by devastating neurological diseases. The Company is using a biology-first approach paired with optimized delivery to develop purpose-built genetic medicines, including programs powered by its novel and proprietary EXACT™ transgene regulation technology. Neurogene is advancing its lead gene therapy program, NGN-401, as a potential best-in-class, one-time treatment for Rett syndrome. For more information, visit neurogene.com or follow on LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20261103409653/en/
Media Contact:
Mike Devine
Executive Director, Corporate Communications
michael.devine@neurogene.com
Investor Contact:
Lina Li
Executive Director, Investor Relations
lina.li@neurogene.com
Source: Neurogene Inc.